HeartSciences (HSCSW) Liabilities and Shareholders Equity (2022 - 2025)

HeartSciences (HSCSW) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $4.2 million; the trailing twelve-month figure through Apr 2026 stood at $16.7 million (down 35.68% YoY), and the FY2025 full-year result was $4.2 million, down 55.56% from the prior year.
• Liabilities and Shareholders Equity retreated to $4.2 million in Q4 2025 per HSCSW's latest filing, from $6.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $10.8 million in Q1 2024 and bottomed at $2.1 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $5.4 million across 4 years, with a median of $5.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 228.38% in 2024, then sank 55.56% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $4.8 million in 2022, then plunged by 50.36% to $2.4 million in 2023, then surged by 228.38% to $7.8 million in 2024, then sank by 45.7% to $4.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $4.2 million, $6.0 million, and $6.4 million for Q4 2025, Q4 2025, and Q3 2025 respectively.